Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inhibrx Biosciences

23.08
+0.01000.04%
Post-market: 23.080.00000.00%19:50 EDT
Volume:193.23K
Turnover:4.35M
Market Cap:334.10M
PE:0.21
High:23.80
Open:22.78
Low:20.84
Close:23.07
Loading ...
Oct 28, 2021

Major Issues Report

8-K - Current report
Oct 12, 2021

Major Issues Report

8-K - Current report
Sep 03, 2021

Major Issues Report

Inhibrx, Inc.
Sep 03, 2021

Major Issues Report

8-K - Current report
Aug 09, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 09, 2021

Major Issues Report

8-K - Current report
Jun 21, 2021

Major Issues Report

8-K - Current report
Jun 09, 2021

Major Issues Report

8-K - Current report
May 17, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
May 13, 2021

Major Issues Report

8-K - Current report
May 13, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Mar 12, 2021

Major Issues Report

8-K - Current report
Mar 12, 2021

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 16, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 16, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 09, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals